Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
ZenaTech Announces Acquisition of Warehouse Software Companies for Integration With AI Drone Solution for Automated Inventory Management
-
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
-
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024
-
Cronos Group Reports 2024 Third Quarter Results
-
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
-
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
-
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
Red Pine Commences 2024-25 Drilling Program at the Wawa Gold Project
-
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
-
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
-
Chart Industries Hosts 2024 Capital Markets Day
-
Incyclix Bio Expands Board of Directors with Appointment of Norman E. Sharpless, MD
-
BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million
-
Bybit Posts Remarkable Volume Surge, Exceeding 639 Billion in Monthly Futures Trading Volume
-
Business trends: Yat Siu, Founder and Executive Chairman of Animoca Brands - The Future of Hong Kong Web3 Lies in Building a Sustainable Digital Asset Environment
-
Eika Boligkreditt AS: Report for the third quarter 2024
-
Howard Hughes Holdings Appoints Jose Bustamante as President of Nevada Region
-
Draganfly to Host Shareholder Update and Q3 Earnings Call
-
Micron Introduces World’s Fastest, Most Energy Efficient 60TB SSD
-
Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results
-
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-
Jeito Capital co-leads €164.5 million ($181.4 million) oversubscribed Series D financing in Alentis Therapeutics to advance clinical development of Anti-Claudin-1 ADCs in solid tumors
-
MT Højgaard Holding A/S: MT Højgaard Holding upgrades outlook for 2024
-
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
-
Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences
-
Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for
-
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
-
Nevada Lithium Significantly Increases the Size and Grade of Lower Zone Inferred Mineral Resources at Bonnie Claire to 25.634 Mt LCE at 3,085 ppm Li. Reports Maiden Indicated Resources of 5.167 Mt LCE
-
HPQ Silica Polvere Fumed Silica Reactor Project Update
-
Prospect Capital Management Partners with iCapital to Expand Investment Advisor Access to Closed End Fund (CEF) and Business Development Company (BDC) Opportunities
-
Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights
-
Experience the Ultimate 420 Festival Celebration with SweetWater's 20th Anniversary Lineup Featuring The Revivalists, Marcus King Band, Greensky Bluegrass, Drive-By Truckers and Cypress Hill at A
-
Shoals Technologies Group, Inc. Reports Financial Results for Third Quarter 2024
-
Opthea’s Wet AMD Program Featured at Ophthalmology Events
-
Churchill Resources Announces Fully Subscribed $2M Private Placement
-
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
-
Kura Sushi USA Announces Pricing of Public Offering of Common Stock
-
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update
-
KOL Collaborators Present Microbix HPV Test-Control Results
-
BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
-
Prospect Capital Corporation to Present at the 2024 Markets Group NYC Private Credit Conference
-
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
-
GHD awarded major federal contract to support Canada’s net-zero fleet goals
-
Creative Realities to Participate in Upcoming Craig-Hallum Conference
-
ATC, an AI-themed Meme Coin, Will Be Listed on CoinW Exchange
-
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
-
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting
-
Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update
-
Spineart Announces the Opening of the Spineart Innovation Center in Dallas, Texas


